

Karin Kast

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/732848/publications.pdf>

Version: 2024-02-01

53
papers

6,598
citations

186265

28
h-index

161849

54
g-index

55
all docs

55
docs citations

55
times ranked

9833
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2402.	7.4	1,898
2	Germline mutations in breast and ovarian cancer pedigrees establish <i>RAD51C</i> as a human cancer susceptibility gene. <i>Nature Genetics</i> , 2010, 42, 410-414.	21.4	638
3	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 134-147.	2.5	513
4	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
5	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
6	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
7	Genome-Wide Association Study in <i>BRCA1</i> Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
8	Prevalence of <i>BRCA1/2</i> germline mutations in 214...401 families with breast and ovarian cancer. <i>Journal of Medical Genetics</i> , 2016, 53, 465-471.	3.2	179
9	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction. <i>Cancer Research</i> , 2010, 70, 9742-9754.	0.9	169
10	Impact of breast cancer subtypes and patterns of metastasis on outcome. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 621-629.	2.5	157
11	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	1.6	152
12	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in <i>BRCA2</i> Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	1.9	148
13	RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA. <i>Nature Communications</i> , 2016, 7, 11752.	12.8	127
14	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	6.3	106
15	Prevalence of deleterious germline variants in risk genes including <i>BRCA1/2</i> in consecutive ovarian cancer patients (AGO-TR-1). <i>PLoS ONE</i> , 2017, 12, e0186043.	2.5	105
16	High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 217-228.	2.5	94
17	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88
18	Prevalence of pathogenic <i>BRCA1/2</i> germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. <i>BMC Cancer</i> , 2018, 18, 265.	2.6	84

#	ARTICLE	IF	CITATIONS
19	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOctoâ€”GBC 84): A randomised phase III trial. <i>European Journal of Cancer</i> , 2019, 106, 181-192.	2.8	84
20	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
21	MLPA screening in the <i>BRCA1</i> gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases. <i>Human Mutation</i> , 2008, 29, 948-958.	2.5	81
22	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	3.5	47
23	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2020, 22, 8.	5.0	41
24	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
25	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	2.5	34
26	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2019, 56, 574-580.	3.2	34
27	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 51.e1-51.e17.	1.3	34
28	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky023.	2.9	33
29	Breast cancer risk in <i>BRCA1/2</i> mutation carriers and noncarriers under prospective intensified surveillance. <i>International Journal of Cancer</i> , 2020, 146, 999-1009.	5.1	32
30	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	6.3	30
31	Validation of the Manchester scoring system for predicting <i>BRCA1/2</i> mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. <i>International Journal of Cancer</i> , 2014, 135, 2352-2361.	5.1	29
32	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26
33	Benefits and risks of a percutaneous endoscopic gastrostomy (PEG) for decompression in patients with malignant gastrointestinal obstruction. <i>Supportive Care in Cancer</i> , 2017, 25, 2849-2856.	2.2	24
34	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	2.5	22
35	Trastuzumab and survival of patients with metastatic breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 303-312.	1.7	20
36	Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey. <i>Cancer</i> , 2020, 126, 4032-4041.	4.1	20

#	ARTICLE	IF	CITATIONS
37	Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. <i>BMC Cancer</i> , 2012, 12, 217.	2.6	19
38	Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1227-1238.	1.7	18
39	Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer. <i>BMC Cancer</i> , 2012, 12, 531.	2.6	12
40	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	6.4	12
41	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. <i>European Journal of Cancer</i> , 2022, 160, 100-111.	2.8	12
42	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. <i>Cancers</i> , 2022, 14, 521.	3.7	12
43	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	2.5	10
44	Changes in classification of genetic variants in BRCA1 and BRCA2. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 279-280.	1.7	8
45	BRCA1/2 missense mutations and the value of in-silico analyses. <i>European Journal of Medical Genetics</i> , 2017, 60, 572-577.	1.3	7
46	Patient-Reported Satisfaction after Prophylactic Operations of the Breast. <i>Breast Care</i> , 2019, 14, 217-223.	1.4	7
47	Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany: A retrospective cohort study. <i>Cancer Medicine</i> , 2021, 10, 7747-7758.	2.8	7
48	Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. <i>Journal of the National Cancer Institute</i> , 2022, 114, 540-552.	6.3	7
49	Familial Breast Cancer - Targeted Therapy in Secondary and Tertiary Prevention. <i>Breast Care</i> , 2015, 10, 27-31.	1.4	5
50	Prevalence of Lynch syndrome in unselected patients with endometrial or ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1299-1303.	1.7	4
51	Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2020, , jmedgenet-2020-107353.	3.2	3
52	Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases. <i>Breast Care</i> , 2022, 17, 153-158.	1.4	1
53	LIFESTYLE und erblicher Brustkrebs. <i>Medizinische Genetik</i> , 2015, 27, 237-243.	0.2	0